A new therapy to re-engage the heart’s natural electrical pathways – instead of bypassing them – could mean more treatment options for heart failure patients who also suffer from electrical disturbances, such as arrhythmias, according to research led by the University of Chicago Medicine.
In a first-ever pilot study, called the His SYNC trial, researchers compared the effectiveness of two different cardiac resynchronization therapies, or treatments to correct irregularities in the heartbeat through implanted pacemakers and defibrillators. The current standard of care, known as biventricular pacing, uses two pacing impulses in both lower chambers, whereas the newer approach, called His bundle pacing, attempts to work toward engaging and restoring the heart’s natural physiology. The two approaches have never before been directly compared in a head-to-head clinical trial.
“This is the first prospective study in our field to compare outcomes between different ways to achieve cardiac resynchronization,” said cardiologist Roderick Tung, MD, FHRS, the Director of Cardiac Electrophysiology & EP Laboratories at the University of Chicago Medicine. “Through His bundle pacing, we’re trying to tap into the normal wiring of the heart and restore conduction the way nature intended. Previously, we have just accepted that we had to bypass it through pacing two ventricles at a time.”
Tung spearheaded the two-year trial with UChicago Medicine cardiologist Gaurav Upadhyay, MD, FHRS, lead author of the study. The trial involved 40 adult patients across seven institutions in the Midwest. The UChicago Medicine team served as the independent coordinating site. Results of the study were presented as a featured late-breaking trial at the Heart Rhythm Society’s annual scientific sessions in San Francisco on May 9. To qualify as a late-breaking trial, the research must be groundbreaking and unique. The study was also published in the Journal of the American College of Cardiology.
A different resynchronization method
Biventricular pacing involves implanting wires, called leads, to simultaneously pace the right and left ventricles of the heart. A pacemaker then sends a timed electric pulse to the two leads with the goal of a synchronized contraction, which closely simulates the heart’s natural heartbeat.
Nevertheless, roughly 30 percent of patients do not respond to biventricular pacing treatment, which has been shown to improve survival in clinical trials.
Tung’s team looked to see if another resynchronization method could help reduce that number by doing a clinical trial comparison between biventricular pacing and His bundle pacing. The latter involves implanting a single lead at the start of the heart’s wiring system, which then naturally branches in two to organically distribute the pacemaker’s electric pulse to both ventricles.
“Permanent His bundle pacing has been around for almost 20 years, but until now there hasn’t been randomized clinical trials on how it compares to biventricular pacing,” Tung said.
For the His SYNC trial, all of the patients met the current guidelines for receiving cardiac resynchronization therapy and were randomly selected to receive either a His bundle pacer or a coronary sinus lead for biventricular pacing. Patients weren’t told which treatment they received.
While the results of the preliminary study did not demonstrate superiority with His-CRT, Tung and his team believe a His bundle pacing approach showed comparable rates of response, warranting further study. The research was limited by a high crossover rate, which was required by the study’s protocol if an adequate lead placement could not be achieved. Nearly half of the patients selected to receive His bundle pacing had to eventually be treated with traditional biventricular pacing due to having a condition called interventricular conduction delay (IVCD). The implantation tools have also not been refined since their introduction 10 years ago.
“We need to learn how to better identify patients who cannot and will not respond to His bundle pacing,” Tung said. “During this pilot study, we learned that the net was cast too wide, and patients with IVCD can’t be corrected and improved by His bundle pacing. His SYNC II, our planned follow-up study, will specifically exclude these patients and this is perhaps the most valuable lesson from the pilot, in addition to estimated treatment effect size.”
In addition, 26 percent of patients chosen to receive biventricular pacing did not, usually because a lead could not be inserted due to the condition of their veins dictated by strict criteria to optimize implantation of left ventricular leads.
Comparing the two approaches
After six months, researchers compared the electrical synchronization and structural function of the two patient groups’ hearts. Although they expected His bundle pacing to be superior, they found no overall significant differences in the two groups, with comparable rates of electrical resynchronization and echocardiographic response.
After one year, there were no differences in the number of hospitalizations or deaths.
Noting the pilot study was limited by its size, Tung says the results indicate further investigation is needed.
“Pilot studies are never meant to be conclusive,” he said. “They’re meant to inform us about effect size, safety and feasibility to help select appropriate patients and power larger studies.”
The Latest on: Heart failure
via Google News
The Latest on: Heart failure
- Serum levels of gamma-glutamyltransferase predict outcome in heart failure with preserved ejection fractionon December 6, 2019 at 2:21 am
Previous studies suggested an association between heart failure (HF) and hepatic disorders. Liver function parameters have been shown to predict outcome in HF with reduced ejection fraction, but their ...
- Study questions beta blockers for half of heart failure patientson December 6, 2019 at 12:09 am
Dec. 6 --Millions of Americans with heart failure take one of the family of beta blocker medications to help ease the condition. But in many cases, could the meds be doing more harm than good? A new ...
- Edwards Lifesciences CEO: Improving procedures for structural heart disease is 'our No. 1 focus'on December 5, 2019 at 9:18 pm
Edwards Lifesciences CEO Michael Mussallem tells CNBC's Jim Cramer that the medical equipment company has prioritized improving care for structural heart disease, which develops through wear and tear.
- Clinical study finds eating within 10-hour window may help stave off diabetes, heart diseaseon December 5, 2019 at 3:34 pm
Metabolic syndrome affects nearly 30 percent of the U.S. population, and increases the risk for type 2 diabetes, heart disease and stroke. But lifestyle interventions such as adopting a healthy diet ...
- Diabetes during pregnancy raises risk of heart disease among kidson December 5, 2019 at 12:54 pm
Children whose mothers had diabetes before or during pregnancy have an increased risk of developing heart disease by age 40, according to a new study. The findings "highlight the importance of ...
- Eating only during a 10-hour window improved health for those with metabolic syndromeon December 5, 2019 at 10:16 am
Ample research has shown that erratic eating patterns, shiftwork, and modern-day habits like get-up-and-go breakfasts and midnight snacks have contributed to obesity, diabetes and heart disease.
- Study Casts Doubt on Use of Common Heart Failure Drugson December 5, 2019 at 10:11 am
Study Casts Doubt on Use of Common Heart Failure Drugs THURSDAY, Dec. 5, 2019 (HealthDay News) -- Millions of Americans with heart failure take one of the family of beta blocker medications to help ...
- Can mammograms show who is at risk of heart failure?on December 5, 2019 at 12:13 am
Mammograms have, so far, had the single role of identifying potentially cancerous tumors in the breast. However, could they also help doctors identify women at risk of heart disease and heart failure?
- Mom's Diabetes Tied to Heart Disease in Kids Years Lateron December 4, 2019 at 3:37 pm
Children whose mothers had diabetes -- including but not limited to gestational diabetes -- showed increased risk of heart disease, a Danish cohort study spanning 40 years found. Rates of ...
- Cholesterol levels predict if under-45s will ever have heart diseaseon December 3, 2019 at 3:38 pm
The study found that when blood concentrations of non-HDL cholesterol – often known as “bad cholesterol” – are higher than 145 milligrams per 100 millilitres before the age 45, a person’s relative ...
via Bing News